Also known as: CagriSema (with semaglutide)
A long-acting amylin analog, mainly tested together with semaglutide.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Amylin is released with insulin and signals fullness. This analog increases satiety through a different pathway from GLP-1.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Fat loss & weight | B | Human trials (smaller, mixed, or approved outside the US) |
| Blood sugar & metabolic | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Subcutaneous weekly
- Half-life
- About 7 days
Reported dosing
Trials titrated to 2.4 mg weekly, alone or combined with 2.4 mg semaglutide.
Timing: Same day each week.
Cycle: Continuous in trials.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Nausea and GI effects, generally milder than GLP-1 drugs alone
Who should avoid it
- Pregnancy
- Unregulated online products
Often combined with
Designed to pair with semaglutide.
Key findings
REDEFINE 1 (2025): about 11.8% weight loss alone and about 20% with semaglutide at 68 weeks.
2026 update
CagriSema was filed with the FDA in Dec 2025, with a decision expected around Q4 2026.
Where it is legal (Oct 2026)
| US | Pending |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Pending |
Sources
Open Cagrilintide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.